Cargando…

Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies

Ischemic stroke, mostly caused by thromboembolic or thrombotic arterial occlusions, is a primary leading cause of death worldwide with high morbidity and disability. Unfortunately, no specific medicine is available for the treatment of cerebral I/R injury due to its limitation of therapeutic window....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lu, Jin, Zhe, Li, Mincheng, Liu, Huifang, Tao, Jie, Xu, Chuan, Wang, Liwei, Zhang, Qiujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797593/
https://www.ncbi.nlm.nih.gov/pubmed/36588739
http://dx.doi.org/10.3389/fphar.2022.1063035
_version_ 1784860716170215424
author Yu, Lu
Jin, Zhe
Li, Mincheng
Liu, Huifang
Tao, Jie
Xu, Chuan
Wang, Liwei
Zhang, Qiujuan
author_facet Yu, Lu
Jin, Zhe
Li, Mincheng
Liu, Huifang
Tao, Jie
Xu, Chuan
Wang, Liwei
Zhang, Qiujuan
author_sort Yu, Lu
collection PubMed
description Ischemic stroke, mostly caused by thromboembolic or thrombotic arterial occlusions, is a primary leading cause of death worldwide with high morbidity and disability. Unfortunately, no specific medicine is available for the treatment of cerebral I/R injury due to its limitation of therapeutic window. Hydroxysafflor yellow A, a natural product extracted from Carthamus tinctorius, has been extensively investigated on its pharmacological properties in cerebrovascular diseases. However, review focusing on the beneficial role of HSYA against cerebral I/R injury is still lacking. In this paper, we reviewed the neuroprotective effect of HSYA in preclinical studies and the underlying mechanisms involved, as well as clinical data that support the pharmacological activities. Additionally, the sources, physicochemical properties, biosynthesis, safety and limitations of HSYA were also reviewed. As a result, HSYA possesses a wide range of beneficial effects against cerebral I/R injury, and its action mechanisms include anti-excitotoxicity, anti-oxidant stress, anti-apoptosis, anti-inflammation, attenuating BBB leakage and regulating autophagy. Collectively, HSYA might be applied as one of the promising alternatives in ischemic stroke treatment.
format Online
Article
Text
id pubmed-9797593
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97975932022-12-30 Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies Yu, Lu Jin, Zhe Li, Mincheng Liu, Huifang Tao, Jie Xu, Chuan Wang, Liwei Zhang, Qiujuan Front Pharmacol Pharmacology Ischemic stroke, mostly caused by thromboembolic or thrombotic arterial occlusions, is a primary leading cause of death worldwide with high morbidity and disability. Unfortunately, no specific medicine is available for the treatment of cerebral I/R injury due to its limitation of therapeutic window. Hydroxysafflor yellow A, a natural product extracted from Carthamus tinctorius, has been extensively investigated on its pharmacological properties in cerebrovascular diseases. However, review focusing on the beneficial role of HSYA against cerebral I/R injury is still lacking. In this paper, we reviewed the neuroprotective effect of HSYA in preclinical studies and the underlying mechanisms involved, as well as clinical data that support the pharmacological activities. Additionally, the sources, physicochemical properties, biosynthesis, safety and limitations of HSYA were also reviewed. As a result, HSYA possesses a wide range of beneficial effects against cerebral I/R injury, and its action mechanisms include anti-excitotoxicity, anti-oxidant stress, anti-apoptosis, anti-inflammation, attenuating BBB leakage and regulating autophagy. Collectively, HSYA might be applied as one of the promising alternatives in ischemic stroke treatment. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797593/ /pubmed/36588739 http://dx.doi.org/10.3389/fphar.2022.1063035 Text en Copyright © 2022 Yu, Jin, Li, Liu, Tao, Xu, Wang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yu, Lu
Jin, Zhe
Li, Mincheng
Liu, Huifang
Tao, Jie
Xu, Chuan
Wang, Liwei
Zhang, Qiujuan
Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title_full Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title_fullStr Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title_full_unstemmed Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title_short Protective potential of hydroxysafflor yellow A in cerebral ischemia and reperfusion injury: An overview of evidence from experimental studies
title_sort protective potential of hydroxysafflor yellow a in cerebral ischemia and reperfusion injury: an overview of evidence from experimental studies
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797593/
https://www.ncbi.nlm.nih.gov/pubmed/36588739
http://dx.doi.org/10.3389/fphar.2022.1063035
work_keys_str_mv AT yulu protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT jinzhe protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT limincheng protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT liuhuifang protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT taojie protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT xuchuan protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT wangliwei protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies
AT zhangqiujuan protectivepotentialofhydroxysaffloryellowaincerebralischemiaandreperfusioninjuryanoverviewofevidencefromexperimentalstudies